HUGE, MASSIVE gain on low volume. We have a pumper people
fold management back to their old shenanigans did a fine job issuing some HYPE!
remember the last time? CEO Crowley said all is going well at FDA for galafold...then SMACK!
I suspect the same thing will happen with the clinical data on EBS...THE CEO IS PUMPING IT BECAUSE THE FDA IS NOT GOING TO ACCEPT IT!!!
All this without any upgrades. Mathew you are in deep doo doo. Where is n16? Probably at CVS obtaining Depends to protect hos soiled panties.
No Way Out
Wow - stellar Pompe data and the FDA agreeing to the better endpoint for EBS and the share price can't break $8? I guess the small cap biotech space is moving back to a wait-and-see approach. I'm marginally skeptical on the EBS trial being successful, but their Pompe treatment is hands-down better than current ERT - they will own the market upon approval.
Well, we obviously know the $8 resistant price.
FOLD is well on the way to earning 0.75 BILLION per year. If a buyout doesn't come this year I would be very surprised
News on FDA talks. Premarket pop. Let's see what happens.
To my knowledge, this will be the only treatment on the market for EB.
Not a bad week for FOLD. I was hoping that once I started to really lose faith that a bottom was getting near.
I think investors are starting to believe that another offering may not be in the cards and that fact should at worst and barring a bad market, keep the stock where it now is. Also the IBB seems to have once again bounced off of the 288 numbers and should head back to 300. Hopefully it finally breaks through there but only time will tell.
FOLD trades well. Yesterday's Pompe news seems to have given the stock an extra boost, almost like it added take over premium.
What in the world is going on?????
No Way Out
The math looks good here. They reported 75 patients on reimbursed Galafold as of Feb 28th, so if you use that number for the average for Q1, the $4.2M of revenue equates to ~$225K per patient annually. They have achieved a 45% penetration rate in Germany in less than a year since launch, so market acceptance is not an issue. 300 patients by year-end will equate to annualized revenues of $60M+ and given the momentum of adding new patients and markets, they should be at 500+ patients by and $100M+ of annualized revenues by mid-2018. It is clear they are stoked with the results they are seeing in the Pompe program, so the only risk here is if the EBS drug flops - they are certainly very reserved with their commentary, but with 95% of the patients carrying forward into the extension study, you would think the drug is working. The caveat is the 9th inning change in primary endpoint for the study - the FDA could screw them over on that?
Israel based PLX is gonna grab US market share from Amicus (if both approved) in Fabry disease. In addition PLX is gonna target ALL Fabry patients as oppose to Galafold that's targeting only 30% patients with amenable mutation. PLX's compound demonsrated so far superior results comparing to Fabrazyme. Amicus though is a great long term play. Steady and slowly up.
About Fabry Disease Fabry disease is an X-linked inherited disease that results from abnormal deposits of a fatty substance called globotriaosylceramide in blood vessel walls throughout the body. It...
Their 1stQ17 presentation says that in Germany final price of Galafold will be effective in 2Q17 and in UK funding is effective on May 23, 2017. Then, Italy and France were added. Expect second quarter revenue to be much higher.
$10 territory soon - hopefully soon .
Excellent news today
ACAD posted a loss of 87 million on 15 million in revenue. It's valued at 3.6 billion now. Does that mean when FOLD hits 15 million in q3 or 4 it will also be valued at 3+ billion??? I'm seriously lost on this one.....
WOW....Trivial revs. again and another massive loss. This thing will be doing another round of dilution soon. Look for $5 again.
They are looking to have about $70 million in revenue within a year, they have a years worth of cash. I think long term you really can't get hurt here
Hmmmm, Migalastat is approved in Europe, Japan, France, etc.......but yet the good old U S of A needs more info and can't approve it as it. It's because they are a bunch of corrupt jerk-offs and someone doesn't want Fold dipping into someone else's pockets. Let's hope for a good CC, glta longs